Delphi Diagnostics Announces New Publication in the European Journal of Cancer
Delphi Diagnostics has published new clinical data in the European Journal of Cancer supporting the Endocrine Activity Index™ Recurrence Risk (EAIRR) as a significant independent predictor of outcomes in patients with hormone receptor-positive, node-positive breast cancer. The study validates EAIRR’s ability to enhance risk stratification beyond the 21-gene Recurrence Score and identify sensitivity to endocrine therapy.
Peer-reviewed manuscript demonstrates the Endocrine Activity IndexTM Recurrence Risk (EAIRR) enhances risk stratification beyond Recurrence Score® and is predictive of endocrine therapy benefit HOUSTON, May 6, 2026 /PRNewswire/ — Delphi Diagnostics today announced the publication of new…